See also:
What is the most important information I should know about Chlorhexidine Gluconate (Wbc)?
You should not use this medication if you are allergic to Chlorhexidine Gluconate (Wbc) gluconate.
If you have periodontal disease, you may need special treatments while you are using Chlorhexidine Gluconate (Wbc) gluconate.
Chlorhexidine Gluconate (Wbc) gluconate oral rinse is not for treating all types of gingivitis. Use the medication only to treat the condition your dentist prescribed it for. Do not share this medication with another person, even if they have the same gum symptoms you have.
Do not give this medication to a child or teenager without a doctor's advice.
Do not add water to Chlorhexidine Gluconate (Wbc) gluconate oral rinse. Do not rinse your mouth with water or other mouthwashes right after using Chlorhexidine Gluconate (Wbc) gluconate.
Avoid eating, drinking, or brushing your teeth just after using this medication.
Do not use any other mouthwash unless your doctor has told you to.
Chlorhexidine Gluconate (Wbc) gluconate can stain teeth, dentures, tooth restorations, your tongue, or the inside of your mouth. Talk with your dentist about ways to remove staining from these surfaces. Stains may be harder to remove from false teeth that have scratches in their surfaces.
Visit your dentist at least every 6 months for preventive tooth and gum care.
See also:
What is the most important information I should know about Sulfadiazine (Wbc)?
Sulfadiazine (Wbc)® is contraindicated in patients who are hypersensitive to silver Sulfadiazine (Wbc) or any of the other ingredients in the preparation.
Because sulfonamide therapy is known to increase the possibility of kernicterus, Sulfadiazine (Wbc)® should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.
See also:
What are the possible side effects of Chlorhexidine Gluconate (Wbc)?
The most common side effects associated with Chlorhexidine Gluconate (Wbc) gluconate oral rinses are (1) an increase in staining of teeth and other oral surfaces, (2) an increase in calculus formation; and (3) an alteration in taste perception; see WARNINGS and PRECAUTIONS.
Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with the use of Chlorhexidine Gluconate (Wbc) gluconate rinse.
The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1.0%.
Among post marketing reports, the most frequently reported oral mucosal symptoms associated with Chlorhexidine Gluconate (Wbc) gluconate oral rinse are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia.
Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using Chlorhexidine Gluconate (Wbc) gluconate oral rinse.
There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using Chlorhexidine Gluconate (Wbc) gluconate oral rinse.
See also:
What are the possible side effects of Sulfadiazine (Wbc)?
Applies to silver Sulfadiazine (Wbc) topical: topical cream
As well as its needed effects, silver Sulfadiazine (Wbc) topical (the active ingredient contained in Sulfadiazine (Wbc)) may cause unwanted side effects that require medical attention.
Severity: ModerateIf any of the following side effects occur while taking silver Sulfadiazine (Wbc) topical, check with your doctor or nurse as soon as possible:
Incidence not known:
Some silver Sulfadiazine (Wbc) topical side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Incidence not known:
Chlorhexidine Gluconate (Wbc)® (Chlorhexidine Gluconate (Wbc) Gluconate
Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine Gluconate (Wbc)® has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Sulfadiazine (Wbc) tablets USP are indicated in the following conditions:
Chancroid
Trachoma
Inclusion conjunctivitis
Nocardiosis
Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine (Wbc) should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful.
Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine.
Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy.
Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups).
Meningococcal meningitis, when the organism has been demonstrated to be susceptible.
Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin.
Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin.
H. influenzae meningitis, as adjunctive therapy with parental streptomycin.
IMPORTANT NOTES
In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media.
Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections.
Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level.
Chlorhexidine Gluconate (Wbc) gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
Chlorhexidine Gluconate (Wbc) gluconate oral rinse is used to treat gingivitis (swelling, redness, bleeding gums). Chlorhexidine Gluconate (Wbc) gluconate is usually prescribed by a dentist.
Chlorhexidine Gluconate (Wbc) gluconate oral rinse is not for treating all types of gingivitis. Use the medication only to treat the condition your dentist prescribed it for. Do not share this medication with another person, even if they have the same gum symptoms you have.
Chlorhexidine Gluconate (Wbc) gluconate may also be used for purposes not listed in this medication guide.
Sulfadiazine (Wbc) is used to treat or prevent infections in many different parts of the body. It belongs to the group of medicines known as sulfonamide antibiotics. It works by preventing the growth of bacteria. However, Sulfadiazine (Wbc) will not work for colds, flu, or other virus infections.
Sulfadiazine (Wbc) is available only with your doctor's prescription.
Each chip contains Chlorhexidine Gluconate (Wbc) gluconate 2.5 mg in a biodegradable matrix of hydrolyzed gelatin (cross-linked with glutaraldehyde).
Chlorhexidine Gluconate (Wbc) also contains glycerin and purified water as excipients.
Chlorhexidine Gluconate (Wbc) gluconate, an antimicrobial agent, is 1, 1'-hexamethylenebis [5-(p-chlorophenyl)biguanide] di-D-gluconate. Molecular Formula: C22H30Cl2N10·2C6H12O7. Molecular Weight: 897.8.
Sulfadiazine (Wbc) is a hydrophilic cream containing micronized silver Sulfadiazine (Wbc) 10 mg/g.
Quantitative composition per 100 g of cream: Silver Sulfadiazine (Wbc) 1 g, polysorbate 60 1 g, polysorbate 80 1 g, glyceryl monostearate 4 g, cetyl alcohol 4 g, propylene glycol 7 g, liquid paraffin 20 g, purified water 62 g.
Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Rinse your mouth with Chlorhexidine Gluconate (Wbc) gluconate twice daily after brushing your teeth.
Measure your dose using the cup provided with the medication. Swish the medicine in your mouth for at least 30 seconds, then spit it out. Do not swallow the mouthwash.
Do not add water to the oral rinse. Do not rinse your mouth with water or other mouthwashes right after using Chlorhexidine Gluconate (Wbc) gluconate.
Chlorhexidine Gluconate (Wbc) gluconate may leave an unpleasant taste in your mouth. Do not rinse your mouth to remove this taste after using the medication. You may rinse the medicine away and reduce its effectiveness.
Use this medication for the full prescribed length of time. Your symptoms may improve before your gingivitis is completely cleared. Chlorhexidine Gluconate (Wbc) gluconate will not treat a viral or fungal infection such as cold sores, canker sores, or oral thrush (yeast infection).
Visit your dentist at least every 6 months for preventive tooth and gum care.
Store Chlorhexidine Gluconate (Wbc) gluconate at room temperature away from moisture and heat.
Use Sulfadiazine (Wbc) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Sulfadiazine (Wbc).
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Use: Labeled IndicationsGingivitis:
Oral rinse: Antimicrobial dental rinse for gingivitis treatmentPeriodontitis: Periodontal chip: Adjunctive therapy to scaling and root planning procedures to reduce pocket depth in patients with periodontitis
Off Label UsesMedication-related osteonecrosis of the jaw (MRONJ), adjunctive therapy:Oral rinse:
Based on a position paper by the American Association of Maxillofacial Surgeons (AAOMS), Chlorhexidine Gluconate (Wbc) gluconate oral rinse is an effective and recommended adjunctive treatment strategy in the management of medication-related osteonecrosis of the jaw (MRONJ) (stage 1 and above [eg, patients with exposed and necrotic bone or fistulae that probes to bone]).
Oropharyngeal decontamination to reduce the risk of ventilator-associated or hospital-acquired pneumonia, Cardiac surgical patients:Oral rinse:Data from a prospective, randomized, double-blind, placebo-control trial and a prospective, randomized, case-controlled trial in patients undergoing coronary artery bypass grafting, valve, or other open heart surgical procedures who received Chlorhexidine Gluconate (Wbc) gluconate 0.12% oral rinse during the perioperative period showed a decreased rate in hospital-acquired pneumonia. However, the trials used in both meta-analyses were heterogeneous and included patients in a variety of settings (eg, cardiothoracic, general ICU, mixed medical-surgical ICU, trauma ICU). The trials also displayed significant variability with Chlorhexidine Gluconate (Wbc) treatment regimens. Chlorhexidine Gluconate (Wbc) concentration varied from 0.12%, 0.2%, or 2% across studies. Frequency of administration, Chlorhexidine Gluconate (Wbc) dosage form (oral rinse, gel, paste, foam), and technique of application also varied across studies. In the US, Chlorhexidine Gluconate (Wbc) gluconate for use in the oral cavity is commercially available only as 0.12% solution. Additional trials may be necessary to further define the role of Chlorhexidine Gluconate (Wbc) gluconate oral rinse in this condition.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Sulfadiazine (Wbc) is used to treat various types of infections such as urinary tract infections, ear infections, meningitis (inflammation of meninges due to bacterial or viral infections), malarial infections and toxoplasmosis (a parasitic disease).
One Chlorhexidine Gluconate (Wbc) is inserted into a periodontal pocket with probing pocket depth (PD) 5 mm or greater. Up to 8 chips may be inserted in a single visit. Treatment is recommended to be administered once every three months in pockets with PD remaining 5 mm or greater. The periodontal pocket should be isolated and the surrounding area dried prior to chip insertion.
The Chlorhexidine Gluconate (Wbc) should be grasped using forceps (such that the rounded end points away from the forceps) and inserted into the periodontal pocket to its maximum depth. If necessary, the Chlorhexidine Gluconate (Wbc) can be further maneuvered into position using the tips of the forceps or a flat instrument. The Chlorhexidine Gluconate (Wbc) does not need to be removed since it biodegrades completely.
In the unlikely event of Chlorhexidine Gluconate (Wbc) dislodgement (in the two pivotal clinical trials, only 8 chips were reported lost), several actions are recommended, depending on the day of Chlorhexidine Gluconate (Wbc) loss. If dislodgement occurs 7 days or more after placement, the dentist should consider the subject to have received a full course of treatment. If dislodgement occurs within 48 hours after placement, a new Chlorhexidine Gluconate (Wbc) should be inserted. If dislodgement occurs more than 48 hours after placement, the dentist should not replace the Chlorhexidine Gluconate (Wbc), but reevaluate the patient at 3 months and insert a new Chlorhexidine Gluconate (Wbc) if the pocket depth has not been reduced to less than 5 mm.
How suppliedChlorhexidine Gluconate (Wbc) (Chlorhexidine Gluconate (Wbc) gluconate) 2.5 mg is supplied as a small, orange-brown, rectangular chip (rounded at one end), in cartons of 20 chips (NDC 52096-001-22). Each chip is individually packed in a separate compartment of an aluminum blister pack.
Store at 20° - 25°C with excursions permitted to 15° - 30° C (59° - 86°F).
Manufactured by: Dexcel® Pharma Technologies Ltd, HaMarpeh 7 St.,Jerusalem 91237, Israel. Distributed by: Adrian Pharmaceuticals, Spring Hill, Florida 34606. Iss. 01/10
Usual Adult Dose for Rheumatic Fever Prophylaxis:
Secondary prophylaxis of rheumatic fever, if patient is intolerant of penicillin:
1 g orally once a day.
The optimal duration has not been definitely determined. The American Heart Association recommends that prophylaxis be continued for at least 5 years or until the patient reaches age 21 (whichever is longer) for rheumatic fever without carditis, and for 10 years in patients with carditis but no valvar heart disease. Prophylaxis is recommended for at least 10 years since the last episode or until the patient reaches age 40 for carditis and persistent valvar disease; lifelong prophylaxis may be required.
Usual Adult Dose for Toxoplasmosis:
Toxoplasmic encephalitis:
Initial dose: Pyrimethamine 200 mg orally once
Maintenance dose:
<60 kg: Sulfadiazine (Wbc) 1 g orally every 6 hours plus pyrimethamine 50 mg orally once a day.
>=60 kg: Sulfadiazine (Wbc) 1500 mg orally every 6 hours plus pyrimethamine 75 mg orally once a day.
In addition, leucovorin 10 to 20 mg/day orally (may increase up to 50 mg/day).
Corticosteroids and anticonvulsants may be given if indicated.
Duration: At least 6 weeks, followed by chronic suppressive therapy.
Usual Adult Dose for Toxoplasmosis -- Prophylaxis:
Secondary prophylaxis after acute treatment of toxoplasmic encephalitis:
Sulfadiazine (Wbc), 500 to 1000 mg orally every 6 hours plus pyrimethamine 25 to 50 mg orally once a day plus leucovorin 10 to 25 mg orally once a day.
Duration: Lifelong in HIV-infected patients. Discontinuation may be considered if the patient has maintained CD4+ T-lymphocyte counts >200 cells/microL following HAART (e.g., >6 months) and has no symptoms of toxoplasmosis. Some experts would also recommend an MRI of the brain.
Usual Pediatric Dose for Rheumatic Fever Prophylaxis:
Secondary prophylaxis of rheumatic fever, if patient is intolerant of penicillin:
> 2 months and <=27 kg: 500 mg orally once a day.
>27 kg: 1 g orally once a day.
The optimal duration has not been definitely determined. The American Heart Association recommends that prophylaxis be continued for at least 5 years or until the patient reaches age 21 (whichever is longer) for rheumatic fever without carditis, and for 10 years in patients with carditis but no valvar heart disease. Prophylaxis is recommended for at least 10 years since the last episode or until the patient reaches age 40 for carditis and persistent valvar disease; lifelong prophylaxis may be required.
Usual Pediatric Dose for Toxoplasmosis:
Congenital toxoplasmosis:
Initial dose: Pyrimethamine 2 mg/kg orally once a day for 2 days
Maintenance dose: Sulfadiazine (Wbc) 50 mg/kg orally twice a day plus pyrimethamine 1 mg/kg orally once a day plus leucovorin 10 mg orally or IM once a day.
Duration: 12 months. After 2 to 6 months, decrease pyrimethamine to 1 mg/kg orally 3 times a week.
Acute acquired toxoplasmosis:
Initial dose: Pyrimethamine 2 mg/kg (maximum 50 mg) orally once a day for 3 days.
Maintenance dose: Sulfadiazine (Wbc) 25 to 50 mg/kg (maximum 1 to 1.5 g/dose) orally every 6 hours plus pyrimethamine 1 mg/kg (maximum 25 mg) orally once a day plus leucovorin 10 to 25 mg orally once a day.
Duration: At least 6 weeks, followed by chronic suppressive therapy.
Usual Pediatric Dose for Toxoplasmosis -- Prophylaxis:
Secondary prophylaxis after acute treatment of toxoplasmic encephalitis:
Sulfadiazine (Wbc) 85 to 120 mg/kg/day (maximum adult dose, 4 to 6 g/day) orally in 2 to 4 divided doses plus pyrimethamine, 1 mg/kg or 15 mg/m2 (maximum dose 25 mg) orally once a day plus leucovorin 5 mg orally every 3 days.
Duration: Lifelong in HIV-infected patients.
See also:
What other drugs will affect Chlorhexidine Gluconate (Wbc)?
Chlorhexidine Gluconate (Wbc) is incompatible with the soap, and detergents containing anionic group (saponins, sodium lauryl sulfate, sodium carboxymethyl cellulose).
Chlorhexidine Gluconate (Wbc) Pharmaniaga is compatible with any medication containing cationic group (cetrimonium bromide, benzalkonium chloride).
See also:
What other drugs will affect Sulfadiazine (Wbc)?
Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Monitor therapy
Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Monitor therapy
Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Avoid combination
Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Monitor therapy
Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Exceptions: Danazol. Monitor therapy
Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Monitor therapy
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Chloroprocaine: May diminish the therapeutic effect of Sulfonamide Antibiotics. Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible. Consider therapy modification
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination
CycloSPORINE (Systemic): Sulfonamide Antibiotics may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic). Monitor therapy
CYP2C9 Inducers (Moderate): May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Monitor therapy
CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). Monitor therapy
Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Consider therapy modification
Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Monitor therapy
Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides. Monitor therapy
Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring. Consider therapy modification
Fosphenytoin-Phenytoin: Sulfadiazine (Wbc) may increase the serum concentration of Fosphenytoin-Phenytoin. Monitor therapy
Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Monitor therapy
Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents. Monitor therapy
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy
Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Monitor therapy
Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Monitor therapy
Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Monitor therapy
Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. Avoid combination
Methenamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine. Avoid combination
Methotrexate: Sulfonamide Antibiotics may enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and therapeutic doses of sulfonamides (eg, trimethoprim/sulfamethoxazole). Patients receiving prophylactic doses of trimethoprim/sulfamethoxazole and methotrexate should be carefully monitored. Consider therapy modification
MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment. Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Monitor therapy
Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Monitor therapy
Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Monitor therapy
Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Monitor therapy
Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Antibiotics. Avoid combination
Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Monitor therapy
Procaine: May diminish the therapeutic effect of Sulfonamide Antibiotics. Avoid combination
Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Monitor therapy
Pyrimethamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics. Monitor therapy
Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Monitor therapy
Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Monitor therapy
Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Monitor therapy
Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Monitor therapy
Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Sulfonylureas: Sulfonamide Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. Monitor therapy
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification
Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Monitor therapy
Vitamin K Antagonists (eg, warfarin): Sulfonamide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. Management: Consider reducing the vitamin K antagonist dose by 10% to 20% prior to starting the sulfonamide antibiotic. Monitor INR closely to further guide dosing. Consider therapy modification
